S. Korean HIV medicine to be sold in China
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Korea Research Institute of Chemical Technology announced Thursday that a domestically developed HIV medicine has recently received regulatory approval for commercialization in China.
This new medicine was first developed by a local research team as part of a project started in 1995, supported by the Ministry of Science and ICT.
In 2006, US pharmaceutical firm Gilead Sciences joined the project and co-developed a treatment candidate in 2008. The technology was sold to local biotech firm Kainos Medicine in 2012, which later signed a contract with Jiangsu Aidea Pharmaceuticals for sales rights in China.
The new treatment consists of non-nucleoside reverse transcriptase inhibitors, which can prevent HIV from making copies of itself.
KRICT confirmed that it is safe to use the treatment in combination with other HIV medicines. The HIV medicine is also potent against the majority of HIV strains found around the globe.
The institute said that the new treatment can be also introduced to countries in Africa and Latin America in the future.
The global HIV drugs market is currently estimated to be worth 16 trillion won ($13.5 billion), in which Gilead Sciences holds around 60 to 70 percent stake, according to KRICT. The market is expected to grow annually by 1.7 percent, the institute added.
By Shim Woo-hyun(ws@heraldcorp.com)
Copyright © 코리아헤럴드. 무단전재 및 재배포 금지.